EGF and its receptor immunoreactivity in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma
| Number of cases with immunoreactivity to | |||
|---|---|---|---|
| Disease entity | EGF | EGFR | EGF + EGFR |
| Abbreviations as in table 1. The scale of immunoreactivity +++ and ++ are regarded as immunopositivity, whereas + and − are regarded as immunonegativity (see Methods). | |||
| SPT | |||
| Benign (n=8) | 6 | 0 | 0 |
| Malignant (n=2) | 1 | 0 | 0 |
| MCN | |||
| Benign (n=4) | 0 | 1 | 0 |
| Malignant (n=8) | 2 | 1 | 1 |
| IPMT | |||
| Benign (n=4) | 3 | 1 | 1 |
| Malignant (n=6) | 5 | 6 | 5 |
| Ductal carcinoma (n=20) | 11 | 12 | 9 |